Denali Therapeutics (DNLI) Receivables - Net (2018 - 2026)

Denali Therapeutics (DNLI) has 8 years of Receivables - Net data on file, last reported at $1.6 million in Q1 2026.

• Receivables - Net for Q1 2026 came in at $1.6 million, down 5.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (down 5.88% YoY), and the FY2025 annual result was $1.6 million, down 26.3% from the prior year.
• Receivables - Net steadied at $1.6 million in Q1 2026 per DNLI's latest filing, from $1.6 million in the prior quarter.
• Over five years, Receivables - Net peaked at $3.4 million in Q2 2023 and troughed at $1.4 million in Q2 2024.
• A 4-year average of $2.0 million and a median of $1.9 million in 2024 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2024 and 2025: Receivables - Net sank 58.82% in 2024, then jumped 35.71% in 2025.
• A 4-year view of Receivables - Net shows it stood at $2.7 million in 2023, then fell by 19.59% to $2.2 million in 2024, then dropped by 26.3% to $1.6 million in 2025, then changed by 0.0% to $1.6 million in 2026.
• Business Quant data shows DNLI's Receivables - Net at $1.6 million in Q1 2026, $1.6 million in Q4 2025, and $1.9 million in Q3 2025.